Brief: Sino Biopharmaceutical Says IND Application Of TRD205 (AT2R Antagonist) Accepted By FDA
25/09/2023 02:48
Sept 25 (Reuters) - Sino Biopharmaceutical Ltd
1177.HK :
* IND APPLICATION OF INNOVATIVE MEDICINE "TRD205 (AT2R
ANTAGONIST)" FILED WITH AND ACCEPTED BY FDA
Source text for Eikon: ID:nHKS87gFtL
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up